The cost of clinical trial data bias/loss, FDA’s new job and the need for bold leadership.
By Dr. Matthew Watson
The scandal of clinical trial data loss is eroding the fundamentals of evidence-based research and clinical medicine.
Before you right this post off as the stuff of conspiracy theories, fear-mongering, and 'alternative world views' consider that this view is shared by the likes of the FDA, the International Committee of Medical Journal Editors, the Cochrane Collaboration, and researchers at institutions like Johns Hopkins School of Medicine.
Here's the underlying premise as succinctly described by author Ben Goldacre:
"Drugs are tested by the people who manufacture them, in poorly designed trials, on hopelessly small numbers of weird, unrepresentative patients, and analysed using techniques that are flawed by design, in such a way that they exaggerate the benefits of treatments. Unsurprisingly, these trials tend to produce results that favour the manufacturer.
When trials throw up results that companies don't like, they are perfectly entitled to hide them from doctors and patients, so we only ever see a distorted picture of any drug's true effects. Regulators see most of the trial data, but only from early on in a drug's life, and even then they don't give this data to doctors or patients, or even to other parts of government. This distorted evidence is then communicated and applied in a distorted fashion."
Authors M. Todwin and J. Abramson summarize it thusly:
"Trials with positive results generally are published more frequently than studies that conclude that a new drug poses greater risks or is no more effective than standard therapy or a placebo. Furthermore, some articles may distort trial findings by omitting important data or by modifying prespecified outcome measures. Lack of access to detailed information about clinical trials can undermine the integrity of medical knowledge."
Here is a great list of very recent resources that may convince you of the merits of this concern:
- What doctors don't know about the drugs they prescribe (2012: TED video)
- The drugs don't work: a modern medical scandal (2012: The Guardian)
- Clinical Trial Data as a Public Good (2012: JAMA [subscription req'd])
- Registering Clinical Trial Results. The Next Step (2010: JAMA [subscription req'd])
- The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience (2012: Plos Medicine)
Source:
http://feeds.feedburner.com/CellTherapyBlog
- 001 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 002 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 003 Google to Invest in Regenerative Medicine [Last Updated On: May 5th, 2010] [Originally Added On: May 5th, 2010]
- 004 Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: May 22nd, 2010] [Originally Added On: May 22nd, 2010]
- 005 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 006 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 007 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 008 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 009 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 12th, 2011] [Originally Added On: February 12th, 2011]
- 010 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 011 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 012 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 013 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 014 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 015 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 016 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 017 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 018 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 019 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 020 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 021 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 022 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 023 Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? [Last Updated On: March 11th, 2012] [Originally Added On: March 11th, 2012]
- 024 Another > $100M month for companies in the cell therapy space [Last Updated On: May 6th, 2012] [Originally Added On: May 6th, 2012]
- 025 Cell-based Cancer Immunotherapies. Some metrics.. [Last Updated On: May 20th, 2012] [Originally Added On: May 20th, 2012]
- 026 Industry-sponsored cardiovascular cell therapies. Some metrics. [Last Updated On: May 27th, 2012] [Originally Added On: May 27th, 2012]
- 027 Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing [Last Updated On: June 17th, 2012] [Originally Added On: June 17th, 2012]
- 028 FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) [Last Updated On: July 29th, 2012] [Originally Added On: July 29th, 2012]
- 029 Is the cell therapy sector outperforming the major indices? [Last Updated On: August 12th, 2012] [Originally Added On: August 12th, 2012]
- 030 Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: September 2nd, 2012] [Originally Added On: September 2nd, 2012]
- 031 Two lessons I learned this week. [Last Updated On: September 16th, 2012] [Originally Added On: September 16th, 2012]
- 032 Anticipated short-term cell therapy industry clinical milestones [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- 033 Cell therapy portfolio outperforms major indices year-to-date [Last Updated On: October 14th, 2012] [Originally Added On: October 14th, 2012]
- 034 CIRM addresses some tough questions. Is it all just glass towers and basic research? [Last Updated On: October 21st, 2012] [Originally Added On: October 21st, 2012]
- 035 GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: November 4th, 2012] [Originally Added On: November 4th, 2012]
- 036 Cell Therapy Industry Group Welcomes its 4,000th member [Last Updated On: November 11th, 2012] [Originally Added On: November 11th, 2012]
- 037 Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. [Last Updated On: December 2nd, 2012] [Originally Added On: December 2nd, 2012]
- 038 A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments [Last Updated On: December 16th, 2012] [Originally Added On: December 16th, 2012]
- 039 The ROI on pant-wearing and other social media tips [Last Updated On: December 16th, 2012] [Originally Added On: December 16th, 2012]
- 040 The Accuracy of Adipose Stem Cell Doses [Last Updated On: December 23rd, 2012] [Originally Added On: December 23rd, 2012]
- 041 Cell Therapy Blog welcomes 2013 [Last Updated On: January 6th, 2013] [Originally Added On: January 6th, 2013]
- 042 2013 Annual Regenerative Medicine Industry Report [Last Updated On: April 21st, 2013] [Originally Added On: April 21st, 2013]
- 043 Commercialization of Regenerative Medicine: Learning from Spin-Outs [Last Updated On: April 28th, 2013] [Originally Added On: April 28th, 2013]
